Rimonabant/Metformin Hydrochloride

利莫那班/盐酸二甲双胍

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRimonabant/Metformin Hydrochloride

Drug Alias NameRimonabant/Metformin利莫那班+盐酸二甲双胍盐酸二甲双胍利莫那班Metformin Hydrochloride/Rimonabant利莫那班盐酸二甲双胍 +[9]

ClassificationSmall molecules

Mechanisms of ActionProtein kinase AMP-activated non-catalytic subunit beta 1 activatorsCannabinoid CB1 receptor antagonists

TargetsCannabinoid CB1 receptorProtein kinase AMP-activated non-catalytic subunit beta 1

Therapy Area/IndicationsDiabetes Mellitus, Type 2

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

Global Highest StatusDiscontinued (Phase 3 Clinical)

Highest Status in ChinaN/A

Originator CompaniesSanofi

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesSanofi

Active IndicationsN/A

Inactive IndicationsDiabetes Mellitus, Type 2

ATC CodeN/A